X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (228) 228
humans (164) 164
cancer (111) 111
cell biology (105) 105
female (83) 83
physiology (62) 62
male (61) 61
biochemistry & molecular biology (56) 56
colorectal cancer (48) 48
prognosis (48) 48
animals (47) 47
health aspects (47) 47
inflammation (47) 47
middle aged (46) 46
expression (44) 44
biomarkers (41) 41
tumors (41) 41
apoptosis (39) 39
pharmacology & pharmacy (39) 39
metabolic syndrome (33) 33
metastases (33) 33
analysis (32) 32
patients (32) 32
risk (32) 32
colorectal carcinoma (31) 31
pathogenesis (31) 31
medical research (30) 30
adult (29) 29
metastasis (29) 29
risk factors (29) 29
care and treatment (28) 28
signal transduction (28) 28
breast cancer (27) 27
cell proliferation (27) 27
development and progression (27) 27
oncology (27) 27
down-regulation (26) 26
medicine, experimental (25) 25
microrna (25) 25
mirna (25) 25
proteins (25) 25
polymorphism (24) 24
signaling (24) 24
chemotherapy (23) 23
micrornas (23) 23
cardiovascular diseases (22) 22
gemcitabine (22) 22
gene expression (22) 22
health risks (22) 22
in-vitro (22) 22
activation (21) 21
biomarkers - blood (21) 21
cardiovascular disease (21) 21
pancreatic cancer (21) 21
aged (20) 20
cells (20) 20
diagnosis (20) 20
drug therapy (20) 20
survival (20) 20
therapeutic applications (20) 20
angiogenesis (19) 19
deoxyribonucleic acid--dna (19) 19
genetic aspects (19) 19
therapy (19) 19
antineoplastic agents - therapeutic use (18) 18
association (18) 18
coronary artery disease (18) 18
cytokines (18) 18
colon-cancer (17) 17
endocrinology & metabolism (17) 17
inhibitors (17) 17
pharmacology (17) 17
anticancer properties (16) 16
genetic research (16) 16
micrornas - genetics (16) 16
biomarkers, tumor - metabolism (15) 15
body mass index (15) 15
medical prognosis (15) 15
signal transduction - drug effects (15) 15
wnt protein (15) 15
blood pressure (14) 14
breast-cancer (14) 14
case-control studies (14) 14
cervical cancer (14) 14
disease control (14) 14
genetic variance (14) 14
health risk assessment (14) 14
iran (14) 14
metabolism (14) 14
mortality (14) 14
research (14) 14
vitamin d (14) 14
adolescent (13) 13
antineoplastic agents - pharmacology (13) 13
c-reactive protein (13) 13
cancer therapies (13) 13
coronary heart disease (13) 13
curcumin (13) 13
drug resistance (13) 13
genes (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of cellular physiology, ISSN 0021-9541, 2018, Volume 233, Issue 1, pp. 378 - 386
The DNA repair protein O6‐Methylguanine‐DNA methyltransferase (MGMT) is suggested to be associated with resistance to alkylating agents such as Temozolomide... 
overall survival | glioblastoma | MGMT methylation | progression‐free survival | progression-free survival | PHYSIOLOGY | NEWLY-DIAGNOSED GLIOBLASTOMA | MULTIFORME | ADJUVANT TEMOZOLOMIDE | CELL BIOLOGY | GENE | RANDOMIZED PHASE-III | PROTEIN EXPRESSION | DOSE-DENSE | CENTRAL-NERVOUS-SYSTEM | RADIOTHERAPY | O-6-METHYLGUANINE-DNA METHYLTRANSFERASE | Glioblastoma - enzymology | Humans | Brain Neoplasms - pathology | DNA Repair Enzymes - genetics | DNA Methylation | Glioblastoma - genetics | Time Factors | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Brain Neoplasms - mortality | Promoter Regions, Genetic | Brain Neoplasms - enzymology | Genetic Predisposition to Disease | Risk Factors | Brain Neoplasms - genetics | Treatment Outcome | Clinical Trials as Topic | Brain Neoplasms - drug therapy | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | DNA Modification Methylases - genetics | Drug Resistance, Neoplasm - genetics | Phenotype | Glioblastoma - pathology | Glioblastoma - drug therapy | Glioblastoma - mortality | Medicine, Experimental | Medical research | Prognosis | Methylation | Glioblastoma multiforme | Methylguanine | Alkylating agents | Glioblastoma | Clinical trials | DNA repair | Patients | Survival | Alkylation | O6-methylguanine-DNA methyltransferase | Medical prognosis | DNA methylation | Biomarkers | DNA methyltransferase | Libraries | Temozolomide | Repair | Risk management | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
Journal Article
CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 39, pp. 4599 - 4600
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 2017, Volume 24, Issue 13, pp. 1321 - 1331
The phosphoinositide 3 kinase AKT mammalian target of rapamycin (PI3K-AKT-mTOR) signaling pathway is an important in the aetiology of pancreatic cancer (PC)... 
Resistance | Biomarkers | PDAC | Pancreatic cancer | PI3K-AKT pathway | MTOR inhibitor | HIGH-DOSE EPIRUBICIN | CHEMISTRY, MEDICINAL | PROSPECTIVE RANDOMIZED-TRIAL | biomarkers | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACUTE MYELOID-LEUKEMIA | OVARIAN-CANCER | resistance | LUNG-CANCER | pancreatic cancer | IN-VITRO | GLUCOSE-METABOLISM | ASCITES TUMOR-CELLS | ANTINEOPLASTIC DRUG LONIDAMINE | METASTATIC BREAST-CANCER | mTOR inhibitor | PHARMACOLOGY & PHARMACY | Pancreatic Neoplasms - metabolism | TOR Serine-Threonine Kinases - metabolism | Humans | Pancreatic Neoplasms - pathology | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Autophagy - drug effects | Pancreatic Neoplasms - drug therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Protein Kinase Inhibitors - toxicity | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | TOR protein | Adenocarcinoma | Gemcitabine | Toxicity | AKT protein | Kinases | Genomic instability | Signal transduction | Cell cycle | Deoxyribonucleic acid--DNA | Cell survival | Stability | Therapeutic applications | Protein biosynthesis | Rapamycin | Metabolism | Gene expression | 1-Phosphatidylinositol 3-kinase | Signaling | Inhibitors | Protein synthesis | Medical prognosis | Wortmannin | Cancer | Apoptosis
Journal Article
CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 39, pp. 4619 - 4625
The c-mesenchymal-epithelial transition factor (c-MET) is involved in the tumorigenesis of various cancers. HGF/Met inhibitors are now attracting considerable... 
HGF/Met inhibitors | HEPATOCYTE GROWTH-FACTOR | ARQ 197 | ADENOVIRAL GENE-THERAPY | I DOSE-ESCALATION | CELL LUNG-CANCER | pancreatic cancer | anti-tumor activity | c-mesenchymal-epithelial transition factor | PHARMACOLOGY & PHARMACY | tumorigenesis | INHIBITOR | TUMOR-GROWTH | SCATTER-FACTOR | RECEPTOR TYROSINE KINASE | MET HGF RECEPTOR
Journal Article
CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 39, pp. 4626 - 4638
Background: Colorectal cancer (CRC) is one of the most common causes of cancer-associated mortality in the world. Anti-tumor effect of curcumin has been shown... 
PATHWAYS | STEM-CELLS | METASTASIS | angiogenesis | Colorectal cancer | MEDIATED ANGIOGENESIS | ROS PRODUCTION | INHIBITS TUMOR-GROWTH | COLON-CANCER | IN-VITRO | xenograft | PHARMACOLOGY & PHARMACY | phytosomal curcumin | EXPRESSION | oxidative stress | cancer-associated mortality | MODULATION
Journal Article